RETATRUTIDE Retatrutide drug/program Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
22:45
Apr 27
Apr 27
Adam May defends retatrutide as a good drug while criticizing a named individual as a charlatan.
Adam May defends retatrutide as a good drug while criticizing a named individual as a charlatan selling unstudied peptides, with no forward-looking market view.
HIGH
15:08
Mar 09
Mar 09
Lilly's retatrutide drives obesity drug growth.
Retatrutide, Lilly's GLP-3, showed phase 3 weight loss up to a third of body weight with some muscle sparing and fewer side effects. It is already being sold by compounding and gray market sources, and Lilly is working to control compounding.
HIGH
About RETATRUTIDE Investor Commentary
Across the available history and selected sources, Buzzberg tracks RETATRUTIDE (Retatrutide drug/program) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Latest voices: A May MD, Andrew Huberman.